Cargando…
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
The failure of matrix metalloproteinase (MMP) inhibitor drug clinical trials in cancer was partly due to the inadvertent inhibition of MMP antitargets that counterbalanced the benefits of MMP target inhibition. We explore how MMP inhibitor drugs might be developed to achieve potent selectivity for v...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361222/ https://www.ncbi.nlm.nih.gov/pubmed/16538215 http://dx.doi.org/10.1038/sj.bjc.6603043 |